Navigation Links
Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim
Date:9/26/2010

f FN, and was as well tolerated, with a similar adverse event profile.(2)

Nivestim is Hospira's second biosimilar and first in Australia. The company's biosimilar erythropoietin, Retacrit™, is currently available in 17 European countries, and Nivestim was approved by the European Commission in June 2010.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. The head office for Hospira in the Asia Pacific region is in Melbourne, Australia. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Hospira's goals with respect to Nivestim. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
2. Hospira Announces CEO Succession Plan
3. Hospira to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Aug. 12
4. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
5. Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections
6. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
7. Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
8. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
9. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
10. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
11. Hospira to Present at Citi 2010 Global Health Care Conference May 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Ill., Oct. 31, 2014  AbbVie (NYSE: ... the third quarter ended Sept. 30, 2014. ... performance of our business with double-digit growth from ... business grew nearly 14 percent in the quarter ... chief executive officer, AbbVie.  "We exceeded our outlook ...
(Date:10/30/2014)... 2014 Stryker Orthopaedics, the Official Joint Replacement ... rounding out its debut year of the relationship at ... AZ. This marks the eleventh tournament stop ... the brand has activated on-site with the "Stryker Mobility ... on the importance of joint health.  ...
(Date:10/30/2014)...  Zimmer Holdings, Inc. (NYSE: ZMH ... team and organizational structure of the combined company following ... that the combined organization will leverage the strength of ... with the new brand to be rolled out across ... The future leadership team is committed to establishing Zimmer ...
Breaking Medicine Technology:AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing ... autoimmune diseases, today announced that its Senior Vice President and ... Annual BIO Investor Forum on October 29, 2009 in San ... available on the company,s website at www.micromet-inc.com ...
... Incorporated (Nasdaq: ARAY ), a global leader in ... an America,s region thereby establishing regionalized management and operational ... formation of this new Americas region, along with the ... each region control of revenue and profitability and responsibility ...
Cached Medicine Technology:Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009 2Accuray Announces Regionalized Management Strategy for Americas 2Accuray Announces Regionalized Management Strategy for Americas 3
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
(Date:10/31/2014)... York, NY (PRWEB) October 31, 2014 ... one of the most remarkable gifts of life — ... platform for matching extraordinary surrogate mothers and donors with ... about individuals in unforeseen circumstances. , It’s a collective ... donors, surrogacy agencies, surrogacy lawyers, and fertility clinics that ...
(Date:10/31/2014)... Triple Board Certified surgeon Dr. Jeffrey ... transform the appearance of military veteran Joseph Jones. ... Plastic and Reconstruction Surgery (AAFPRS) Faces of Honor program, ... hair Jones lost during an IED blast almost ten ... procedure, valued around $16,000, took Dr. Epstein over eight ...
(Date:10/31/2014)... October 31, 2014 BCC Research ( http://www.bccresearch.com ... AIR QUALITY MARKET , the U.S. indoor air quality (IAQ) ... with a compound annual growth rate (CAGR) of 7% over ... to grow at a CAGR of 7.4%. , Since ... toxic mold, the outbreak of infectious diseases such as bird ...
(Date:10/31/2014)... 2014 Radiology and EMR Integration ... difference between diagnostic imaging centers but Connectivity is ... DigitalOne. “Differentiation is critical in all businesses ... you consider the intense competition and the downward ... will stand-out from the competition by fully integrating ...
Breaking Medicine News(10 mins):Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... (Dec. 20, 2007) -- Using new approaches, an interdisciplinary ... in New York City has gained a view of ... difficulty in patients with borderline personality disorder -- shedding ... early days yet, but the work is pinpointing functional ...
... More Benefit Online Nurse Community, SAN DIEGO, ... professionals to connect with their peers are growing ... site rising to the top,designed exclusively for nursing ... with their peers. NurseConnect, (http://www.nurseconnect.com ) is a ...
... 21 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... application (sNDA) with the U.S. Food and Drug,Administration ... with,previously untreated multiple myeloma (MM). The filing is ... VISTA(1) trial, one of the largest,international, randomized clinical ...
... MURRYSVILLE, Pa., Dec. 21 RESPIRONICS, INC.,(Nasdaq: RESP ... merger,agreement pursuant to which Royal Philips Electronics (AEX: PHI, ... all of the outstanding,shares of Respironics for USD 66.00 ... approximately USD 5.1 billion. The offer price represents a,premium ...
... Upon an ex parte motion,by the Service Employees ... (TRO) was issued late on Thursday, December 20,by ... Michigan,enjoining the Michigan Department of Community Health, Manor ... Group from taking certain actions related to,completing the ...
Cached Medicine News:Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 3Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 4Health News:Professional Networking Web Site, NurseConnect.com Launches Innovative Features 2Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 2Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 3Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 4Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 5Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5Health News:Manor Care To Vigorously Contest TRO 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: